Specialty Medications in Development

Oct 29, 2015
A look at the current and future specialty medication landscape.
Tags
  • Commercial
  • Asthma
  • Cancer
  • High Blood Cholesterol
  • Hepatitis C

Glow Cap Article

Specialty drug spending increased a record 31% in 2014, and we forecast spending increases of 21%-22% each year for the next three years. Specialty medications managed through the pharmacy benefit account for more than 32% of a plan’s total pharmacy spend. By 2019, we anticipate that percentage could increase to nearly half of a plan’s total pharmacy spend.

With these current and forecasted spending growth rates, it is critical for plans to understand the pipeline of specialty medications and create a strategy managing these new, costly therapies.

Recently, Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics, provided a comprehensive overview of the specialty pharmacy landscape at the Academy of Managed Care Pharmacy Nexus Conference in Orlando.

Managed Healthcare Executive published a two-part summary of her presentation, highlighting six noteworthy specialty medication approvals and four key conditions that could be greatly impacted by medications in the pipeline.

Author Bio

Lab Staff
comments powered by Disqus